Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582451 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
NCT01582451 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 466 participants.
The verdict
NCT01582451, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
Study Summary
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach blood sugar targets without low blood sugar episodes at night * The rate of low blood sugar episodes reported over a 24-hour period
Interventions
- DRUG Insulin glargine
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582451
The ClinicalTrials.gov registry entry for NCT01582451 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine is the first listed.
NCT01582451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582451 about?
NCT01582451 is a clinical study titled "A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus". The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach bloo...
What is the current status of trial NCT01582451?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2012-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01582451?
The interventions under investigation include: Insulin glargine (DRUG), LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01582451?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.